Recent Developments in Dementia Treatment
The Food and Drug Administration (FDA) has recently granted full approval to a novel Alzheimer's treatment known as lecanemab. This medication has demonstrated the ability to moderately decelerate cognitive and functional decline in individuals with early-stage Alzheimer's disease. It received traditional approval from the US FDA for Alzheimer's disease treatment based on Phase 3 data derived from the Clarity AD clinical trial. Additionally, recent research suggests that older individuals with higher levels of triglycerides, a type of fat in the bloodstream, may experience a reduced risk of dementia and a slower cognitive decline over time when compared to those with lower triglyceride levels.